Hologic stock hits 52-week low at $57.36 amid market shifts

In a challenging market environment, Hologic Inc . (NASDAQ:HOLX) stock has touched a 52-week low, reaching $57.36. Despite the recent decline, InvestingPro analysis shows the company maintains a GREAT financial health score, though 13 analysts have recently revised their earnings expectations downward. This downturn reflects a significant retreat from the company's better-performing days, with the stock down 17.73% year-to-date. Investors are closely monitoring Hologic's performance as the company navigates through the headwinds that have pressured the healthcare sector, leading to this new low point in the stock's yearly trajectory. Trading at a P/E ratio of 18.19 with strong free cash flow yield, InvestingPro analysis suggests the stock is currently undervalued. The market will be watching for Hologic's strategic responses to these conditions, which could potentially influence the stock's recovery and future performance. Get the complete picture with InvestingPro's comprehensive research report, part of its coverage of 1,400+ US stocks.

In other recent news, Hologic Inc. announced that its Aptima SARS-CoV-2 test has received 510(k) clearance from the FDA, marking a significant regulatory milestone for the company. This clearance underscores the test's utility in managing COVID-19, now in an endemic phase. Additionally, Hologic reported its first-quarter financial results for fiscal year 2025, where revenue met prior announcements and earnings per share exceeded consensus estimates. However, the company revised its full-year revenue forecast downward, citing slower growth in its Breast Health segment and currency-related headwinds.

Mizuho (NYSE:MFG) Securities adjusted its outlook on Hologic by lowering the stock price target to $83 from $87, maintaining an Outperform rating. The adjustment follows the company's revised forecasts, highlighting challenges in Breast Health sales due to a weaker hospital spending cycle and previous chip shortages. Despite these challenges, the Mizuho analyst remains optimistic about potential recovery, expecting growth to resume by the 2026 fiscal year.

In executive news, Hologic announced the upcoming retirement of its General Counsel, John Griffin, who will transition to a Special Advisor role. Anne Liddy is set to take over as General Counsel on May 1, 2025. Furthermore, Hologic has added Wayde McMillan to its Board of Directors, enhancing its strategic leadership with his extensive financial expertise. Meanwhile, Needham maintained a Hold rating on Hologic stock, reflecting cautious optimism about the company's future performance amid current headwinds.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.